StreetInsider.com News Articles

TransMedics Group (TMDX) PT Raised to $80 at Stifel on Q2 Top-line Beat

Thu, 18 Jun 2026 07:06:03 -0400

Stifel analyst Thomas Stephan raised the price target on TransMedics Group (NASDAQ: TMDX) to $80.00 (from $75.00) while maintaining a Hold rating.

The analyst commented, "Strengthening flight data points to a solid 2Q26 top-line beat ($195M versus Street’s $183M), in our view—however, the rebound in TMDX trends seemingly is market-driven as donor growth and US transplant volumes were strong in May.As a result, the 2Q26 implied rate of TMDX's share gains remains relatively subdued compared to recent history. Our 2026 market growth and share analysis only implies moderate upside to the revenue guidance midpoint, and we have a downward bias in

TransMedics Group (TMDX) PT Raised to $80 at Stifel on Q2 Top-line Beat

Thu, 18 Jun 2026 07:06:03 -0400

Stifel analyst Thomas Stephan raised the price target on TransMedics Group (NASDAQ: TMDX) to $80.00 (from $75.00) while maintaining a Hold rating.

Form 4 TransMedics Group, Inc. For: Jun 15 Filed by: Gunderson Thomas J.

Wed, 17 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260617/26660086.html

Form 4 TransMedics Group, Inc. For: Jun 15 Filed by: Gunderson Thomas J.

Wed, 17 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260617/26660086.html

Form 144 TransMedics Group, Inc. Filed by: Gunderson Thomas J.

Mon, 15 Jun 2026 18:06:00 -0400

si-local-file:///var/storage/secattach/20260615/26648862.html

Form 144 TransMedics Group, Inc. Filed by: Gunderson Thomas J.

Mon, 15 Jun 2026 18:06:00 -0400

si-local-file:///var/storage/secattach/20260615/26648862.html

Form SD TransMedics Group, Inc.

Fri, 29 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260529/26575445.html

Form SD TransMedics Group, Inc.

Fri, 29 May 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260529/26575445.html

TransMedics Group (TMDX) PT Lowered to $75 at Stifel

Tue, 26 May 2026 07:39:28 -0400

Stifel analyst Thomas Stephan lowered the price target on TransMedics Group (NASDAQ: TMDX) to $75.00 (from $85.00) while maintaining a Hold rating.

The analyst commented, "We spoke with four US heart transplant KOL surgeons, who primarily attributed recent heart market weakness to the growing mix toward DCD—as well as fewer opioid-related deaths. We expect near-term market pressure to continue but remain optimistic about an intermediate-term return to more-normal growth.Two surgeons participated in XVIVO's HOPE US PRESERVE study and another two were OCS-focused—yet the sentiment around XVIVO’s data/device was strong/positive across all KOLs (comprehensive PRESERVE feedback can be found HERE).The doctors’ expected

TransMedics Group (TMDX) PT Lowered to $75 at Stifel

Tue, 26 May 2026 07:39:28 -0400

Stifel analyst Thomas Stephan lowered the price target on TransMedics Group (NASDAQ: TMDX) to $75.00 (from $85.00) while maintaining a Hold rating.

Form 4 TransMedics Group, Inc. For: May 20 Filed by: Gunderson Thomas J.